Interpretation of advances in immune therapy for non-small cell lung cancer at the 2025 European Lung Cancer Congress
- VernacularTitle:2025年欧洲肺癌大会非小细胞肺癌免疫治疗进展解读
- Author:
Wen LIU
1
;
Jiayu LU
2
;
Xuxu ZHANG
3
;
Xinyao XU
4
;
Jipeng ZHANG
4
;
Wei LI
4
;
Guizhen LI
4
;
Bo BAO
4
;
Qiang LU
4
Author Information
1. 1. Basic Medical College, Air Force Medical University, Xi an, 710032, P. R. China 2. Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi an, 710038, P. R. China
2. Basic Medical College, Air Force Medical University, Xi an, 710032, P. R. China
3. 1. Basic Medical College, Air Force Medical University, Xi an, 710032, P. R. China 3. Shaanxi University of Chinese Medicine, Xianyang, 712046, Shaanxi, P. R. China
4. Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi an, 710038, P. R. China
- Publication Type:Journal Article
- Keywords:
Perioperation;
non-small cell lung cancer;
immune therapy;
targeted therapy;
interpretation
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2025;32(08):1063-1071
- CountryChina
- Language:Chinese
-
Abstract:
The 2025 European Lung Cancer Congress (ELCC) convened in Paris, France, centering on the optimization and innovation of immunotherapy for non-small cell lung cancer (NSCLC). Key topics at the congress included the application strategies for perioperative immunotherapy, breakthroughs in combination therapy models for advanced NSCLC, and the emerging roles of biomarkers in predicting diverse treatment outcomes. This paper integrates data from several key pivotal studies to systematically analyze the clinical value of neoadjuvant therapy within the perioperative setting, the potential of targeted combination regimens, and the challenges of managing drug resistance, thus offering new directions for clinical practice.
